Hegele A - Search Results

1

[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].

Siebels M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H; Deutsche Gesellschaft für Immun- und Targeted Therapie e.V. (DGFIT). Siebels M, et al. Among authors: hegele a. Urologe A. 2011 Sep;50(9):1110-7. doi: 10.1007/s00120-011-2553-3. Urologe A. 2011. PMID: 21559917 German.

2

[Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].

Siebels M, Staehler M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H; Deutsche Gesellschaft für Immun- und Targeted Therapie e.V. (DGFIT). Siebels M, et al. Among authors: hegele a. Aktuelle Urol. 2010 Mar;41(2):122-30. doi: 10.1055/s-0029-1224676. Epub 2009 Nov 20. Aktuelle Urol. 2010. PMID: 19937556 German.

3

[Gender-specific characteristics and survival of renal cell carcinoma].

Schrader AJ, Sevinc S, Olbert PJ, Hegele A, Varga Z, Hofmann R. Schrader AJ, et al. Among authors: hegele a. Urologe A. 2008 Sep;47(9):1182, 1184-6. doi: 10.1007/s00120-008-1832-0. Urologe A. 2008. PMID: 18679648 German.

4

[DGFIT: Immune and targeted therapy in urologic oncology – what can be expected?].

Hegele A, Heinzer H, Rüttinger D, Siebels M. Hegele A, et al. Aktuelle Urol. 2012 Jul;43(4):219-26. doi: 10.1055/s-0032-1322498. Aktuelle Urol. 2012. PMID: 23035262 German.

5

[Effects of botulinum toxin type A in the single and repeated treatment of overactive bladder. A prospective analysis].

Frohme C, Varga Z, Olbert P, Schrader AJ, Hofmann R, Hegele A. Frohme C, et al. Among authors: hegele a. Urologe A. 2010 May;49(5):639-44. doi: 10.1007/s00120-009-2208-9. Urologe A. 2010. PMID: 20182692 German.

6

Metastatic non-clear cell renal cell carcinoma: current therapeutic options.

Schrader AJ, Olbert PJ, Hegele A, Varga Z, Hofmann R. Schrader AJ, et al. Among authors: hegele a. BJU Int. 2008 Jun;101(11):1343-5. doi: 10.1111/j.1464-410X.2008.07462.x. Epub 2008 Jan 30. BJU Int. 2008. PMID: 18241246 Review.

7

[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].

Schrader AJ, Heidenreich A, Hegele A, Olbert P, Varga Z, Hofmann R. Schrader AJ, et al. Among authors: hegele a. Aktuelle Urol. 2006 Nov;37(6):429-35; quiz 423-4. doi: 10.1055/s-2006-932207. Aktuelle Urol. 2006. PMID: 17099831 German.

8

Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches.

Schrader AJ, Varga Z, Hegele A, Pfoertner S, Olbert P, Hofmann R. Schrader AJ, et al. Among authors: hegele a. J Cancer Res Clin Oncol. 2006 Mar;132(3):137-49. doi: 10.1007/s00432-005-0058-4. Epub 2005 Nov 25. J Cancer Res Clin Oncol. 2006. PMID: 16308709 Review.

9

[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].

Keil C, Götze L, Olbert P, Hofmann R, Nockher WA, Hegele A. Keil C, et al. Among authors: hegele a. Urologe A. 2015 Jun;54(6):811-8. doi: 10.1007/s00120-014-3711-1. Urologe A. 2015. PMID: 25503897 Clinical Trial. German.

10

[Application monitoring of the use of sorafenib in papillary renal cell carcinoma].

Schrader AJ, Hegele A, Olbert P, Buer J, Jeron A, Hofmann R. Schrader AJ, et al. Among authors: hegele a. Urologe A. 2007 Sep;46(9):1291. doi: 10.1007/s00120-007-1500-9. Urologe A. 2007. PMID: 17668165 German. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135 results

Search Page

Filters